Callitas Therapeutics

Callitas Therapeutics was a clinical-stage pharmaceutical and healthcare company focused on developing technologies for sexual health, wellness, and weight management. The company's portfolio included ToConceive, an FDA-cleared medical device for fertility, and C-103, a reformulated version of orlistat for weight loss. Additionally, Callitas developed delivery platforms like CannaStrips for the administration of cannabinoids. While once publicly traded on the Canadian Securities Exchange, the company has since ceased active operations and its primary digital presence is no longer maintained. The company's strategy involved repurposing existing drugs and utilizing proprietary delivery systems to address unmet needs in the consumer health market.